Latest News

  • INSIGHTS

    16 Mar 2026

    Inside the High-Tech Rebirth of ADCs

  • PARTNERSHIPS

    10 Mar 2026

    New Roche Deal Targets B7H3 Tumors Worldwide

  • INNOVATION

    20 Feb 2026

    Taiho’s Calculated Gamble on Precision ADCs

  • REGULATORY

    12 Feb 2026

    A Faster Track for Myeloma Treatments?

Can Better ADC Engineering Unlock Solid Tumors?

Solve Therapeutics branding displayed on a Nasdaq digital billboard

INVESTMENT

9 Feb 2026

Solve Therapeutics raises $120M with backing from MSD and others, betting that smarter ADC design can finally unlock solid tumors

AbbVie headquarters signage representing pharmaceutical oncology strategy

INSIGHTS

24 Jan 2026

AbbVie’s RemeGen Bet Highlights a Shift in Cancer Strategy

AbbVie’s RC148 deal with RemeGen reflects a broader push to combine ADCs with complementary drugs for longer lasting cancer responses

Digital visual of lungs showing cancer sites relevant to ADC lung cancer trials

RESEARCH

19 Jan 2026

Pfizer Moves Deeper Into ADCs With Pivotal Lung Cancer Trials

Pfizer advances an investigational ADC into Phase III lung cancer trials, testing monotherapy and combination approaches amid rising compe...

Aktis Oncology signage at Nasdaq symbolising biotech partnership and IPO plans

PARTNERSHIPS

14 Jan 2026

In Precision Oncology, Smart Alliances Are Beating Big Buys

Lilly’s stake in Aktis’s planned IPO shows how oncology partnerships are reshaping innovation by blending science, capital, and caution

FDA signage with vial representing orphan drug incentives in oncology regulation

REGULATORY

8 Jan 2026

Orphan Drug Incentives Shape Next Wave of Cancer Deals

US orphan drug incentives are quietly steering ADC development and deal-making, nudging firms toward rare cancers as precision oncology ac...

Graphic representation of antibody drug conjugates used in targeted cancer drug development

INVESTMENT

14 Nov 2025

A Small Deal With a Big Message for US Cancer Drugmakers

Day One’s Mersana buy shows how US drugmakers are moving earlier to lock up promising antibody-drug conjugates

Digital illustration of cancer cells analysed using AI for ADC precision oncology

TECHNOLOGY

5 Nov 2025

AI May Be the Missing Link in ADC Cancer Precision

AI-guided tissue analysis is sharpening patient selection, cutting trial risk, and speeding more precise ADC cancer drug development

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.